Alzheimer’s Disease (AD) Matters Now
At Eisai, we are driven by our unwavering commitment to improving the lives of people who are living with Alzheimer’s disease (AD). Built on a decades-long legacy of research and innovation in AD, we are driven by our human health care (hhc) mission to put patients and their families first, working every day to shape the future of how this progressive, fatal disease is understood, diagnosed, and treated.
What Is Alzheimer’s Disease?
Alzheimer’s disease is progressive. Even in the early stages, AD can begin to interfere with daily life.
AD is linked to the build-up of amyloid protein in the brain, which over time can damage brain cells and clump together into harmful amyloid brain plaques.
Various mechanisms have been proposed over the years to describe the pathogenic events that lead to the development of AD, all of which suggest that the presence of Aβ and tau, synaptic failure, and neuronal dysfunction are common features of AD and play a pivotal role in cognitive dysfunction.
Learn more about the progression of AD
What Does Alzheimer’s Disease Look Like?
There are many complexities in the AD landscape: risk factors, early symptoms, causes, diagnoses, and stages. Early detection is one of the keys to the right person, receiving the right medication, at the right time.
The Key to Our Progress in Alzheimer's Treatment? Research Excellence.
When it comes to understanding the science of memory, no detail is too small. To learn more, watch our LinkedIn Live stream on the real-world implications of study design methods and data evaluation in Alzheimer’s disease clinical research.
Understanding the Science of Alzheimer’s Disease
Learn more about the mechanisms behind neurogenerative diseases like Alzheimer’s and dementia, and the science that goes into developing the future of treatment.
Unlocking Alzheimer’s: Understanding the Science
Experts Dung Trinh, MD, and Darren Gitelman, MD, joined Eisai’s Susan De Santi, PhD, for a LinkedIn Live event where they discussed numerous aspects of Alzheimer’s disease (AD), including mechanism of disease, blood-based biomarkers, the role of protofibrils in AD progression and evaluating clinical data in AD.
Learn About The Underlying Mechanism Of Alzheimer’s Disease
Research has shown that protofibrils play a key role in the neurodegenerative process of Alzheimer’s disease (AD) pathophysiology. Expert neurologists Dennis Selkoe, MD, and Arif Dalvi, MD, joined Eisai’s Michael Irizarry, MD, MPH, to discuss where protofibrils fit in the amyloid-beta pathway and how their neurotoxic effects contribute to AD progression.
Expert Discussions on Alzheimer’s
Take a deeper dive into the evolving concept of meaningful benefit in AD and the growing importance of a patient-centered care framework from some of the leading voices in the field.
Assessing Meaningful Benefits in Early Alzheimer's Disease (AD)
Click on the video on the right to hear expert discussions on assessing meaningful benefits in early AD using a holistic approach that incorporates multiple stakeholder perspectives: view full series here
Patient-Centered Care Framework in Alzheimer's Disease (AD)
Click on the video on the right to hear experts from around the world discuss the urgent need for a patient-centered framework in AD to ensure a timely diagnosis and appropriate patient identification. The time is now: view full series here
Learn About The Underlying Mechanism Of Alzheimer’s Disease
Research has shown that protofibrils play a key role in the neurodegenerative process of Alzheimer’s disease (AD) pathophysiology. Expert neurologists Dennis Selkoe, MD, and Arif Dalvi, MD, joined Eisai’s Michael Irizarry, MD, MPH, to discuss where protofibrils fit in the amyloid-beta pathway and how their neurotoxic effects contribute to AD progression.
Dig Deeper: Resources For HCPs
Our Products